| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Endocrinology and Metabolism, Department of Medicine (S.S., W.S., A.T., C.R.); Department of Pathology (W.C.); and Epidemiology Unit (A.G.), Faculty of Medicine, Prince of Songkla University, Hat-Yai, Songkhla 90110, Thailand
Address all correspondence and requests for reprints to: Supamai Soonthornpun, M.D., Division of Endocrinology and Metabolism, Department of Medicine, Prince of Songkla University, Hat-Yai, Songkhla 90110, Thailand. E-mail: ssupamai{at}ratree.psu.ac.th.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
|
| Subjects and Methods |
|---|
|
|
|---|
75-g OGTT
The 75-g OGTT was carried out after a 10-h overnight fast. Subjects ingested 75 g glucose in 300 ml water over a period of less than 5 min. Blood samples were collected through an indwelling catheter before and at 30-min intervals after the glucose load over a 3-h period for determination of plasma glucose and serum insulin. The subjects voided just before the ingestion of glucose and were seated during the test. Urine was collected at the end of OGTT for the determination of urinary glucose.
Euglycemic hyperinsulinemic clamp
Glucose clamp was carried out as described originally by DeFronzo et al. (8). The subjects were studied in the recumbent or supine position at 0900 h after a 10-h overnight fast. An iv catheter was placed in an antecubital vein for infusion of insulin and glucose. Another catheter was placed in the contralateral hand for blood sampling. This hand was placed in a warming box thermostatically controlled at 60 C to arterialize the blood. An insulin solution (Actrapid, Novo Nordisk, Copenhagen, Denmark) was prepared with normal saline at a concentration of 0.3 U/ml. A 10-min priming insulin infusion was followed by a constant infusion of 50 mU/m2 surface area·min for 110 min. The plasma glucose concentration was measured at the bedside every 5 min, and an infusion of 20% dextrose was adjusted to maintain the plasma glucose concentration at 5 mmol/liter according to a computerized algorithm with a coefficient of variation less than 5%. Blood samples were also collected at the beginning and every 10 min during the last hour of study for determination of serum insulin concentrations.
Assays
Glucose concentrations were analyzed by the glucose oxidase method using Synchron CX-3
(Beckman Coulter, Inc., Fullerton, CA). Serum insulin concentrations were determined by RIA (Diagnostic Products, Los Angeles, CA). Intraassay coefficients of variation were 5.8% and 4.2% at mean concentrations of 300 and 960 pmol/liter, and interassay coefficients of variation were 8.0% and 7.0% at mean concentrations of 280 and 1174 pmol/liter.
ISIOGTT
Assuming that there was no insulin available in the body and 75 g glucose are ingested, the plasma glucose concentration would be very high, as shown in Fig. 1
. Lets call this level of plasma glucose concentration the postloading plasma glucose concentration without insulin (PPGC-without insulin). In reality, after glucose is ingested, the plasma glucose concentration responses during OGTT would be much lower than the PPGC-without insulin. The appearance of glucose or the area under the glucose curve (AUCglu) represents glucose that comes from hepatic glucose production and unused glucose. Therefore, the peripheral glucose utilization is the area above the glucose curve (AACglu) less urinary glucose during the OGTT. PPGC-without insulin originates from the fasting plasma glucose concentration (FPG) plus the estimated plasma glucose concentration when 75 g glucose are ingested in the absence of insulin, the level of which is calculated from the glucose load divided by the extracellular fluid volume or glucose space (Eq I
). The glucose load is 0.75 multiplied by 75,000 mg, which is converted to millimoles by dividing by 180. The factor 0.75 is the proportion of ingested glucose absorbed by the intestine in 3 h, which is approximately 75% (7, 9, 10, 11). The glucose space is 0.19 liters of body weight (BW) in kilograms:
![]() |
![]() |
![]() |
![]() |
![]() |
|
Glucose disposal rates (M) were calculated at 20-min intervals (Eq V
) and averaged over the last 60 min of the glucose clamp study. The steady state serum insulin levels (I) were averaged over the same period. ISIClamp is the ratio of the mean glucose disposal rates and steady state serum insulin levels (M/I):
![]() |
![]() |
Statistical analysis
Data were expressed as the mean ± SD. Pearsons correlation coefficients were used for studying the strength of association. Comparisons between two correlation coefficients were tested by the use of Z = z1 - z2/
, as described in Zar et al. (12). P < 0.05 was considered statistically significant. Statistical analysis was performed using SPSS 9.0 for Windows (SPSS, Inc., Chicago, IL).
| Results |
|---|
|
|
|---|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Based on the facts that compensatory hyperinsulinemia is normally found in the insulin resistance state and that plasma glucose concentrations are similar in subjects with normal glucose tolerance, insulin levels, which represent the ability of pancreatic ß-cells to secrete insulin, are therefore associated with insulin resistance. Previous studies showed that fasting insulin, either alone or combined with fasting glucose, provided a reasonable ISI (13, 14, 15, 16). Likewise, several studies have demonstrated that HOMA and QUICKI had a good correlation with ISIClamp (2, 4, 5, 17). In contrast, this study demonstrated that both HOMA and QUICKI had a weak correlation with ISIClamp. The most likely explanation for this discrepancy is that the subjects in this study were lean and had low fasting insulin concentrations (mean fasting insulin, 53 pmol/liter), whereas the subjects in previous studies that reported good results by HOMA and QUICKI were obese and had high fasting insulin levels (mean fasting insulin, 76122 pmol/liter). As the intraassay coefficient of variation of insulin determination at low concentrations was high, a high variability in determinations at low levels of insulin could possibly cause a weak correlation between HOMA or QUICKI and ISIClamp in this study. This finding was in agreement with several investigators. Katz et al. (5) found that the correlation between QUICKI and ISIClamp was lower in nonobese subjects (r = 0.49) compared with obese subjects (r = 0.89). Likewise, Burn et al. (15) demonstrated that the correlation between ISI that used fasting insulin with or without fasting glucose and ISIClamp was higher in an obese group than in a group consisting of both lean and obese subjects. Furthermore, the correlation also depends on the range of insulin sensitivity in the study population. If this is wide, the correlation is greater than if it is narrow (18).
In accordance with previous reports (2, 3), our data showed that the ISIOGTT by which both fasting and postload glucose and insulin concentrations were included (i.e. Cederholm, Gutt, Belfiore, and Matsuda) had higher correlation with ISIClamp than those that included only fasting glucose and insulin concentrations (i.e. HOMA and QUICKI). This is because fasting glucose concentrations are largely determined by basal hepatic glucose production (11, 19), which is inversely correlated with hepatic insulin sensitivity. The product of fasting glucose and fasting insulin (for HOMA) or summation of log fasting glucose and log fasting insulin (for QUICKI) therefore provides a measure of hepatic insulin sensitivity rather than peripheral insulin sensitivity. Matsuda and DeFronzo (2) demonstrated that there were a significant number of individuals with normal or near normal hepatic insulin sensitivity, but with impaired peripheral insulin sensitivity and vice versa. Therefore, ISIOGTT, which includes postload glucose and insulin concentrations, would provide a more reasonable estimate of peripheral insulin sensitivity than those including only fasting glucose and insulin concentrations.
Recently, Stumvoll et al. (4) developed an ISIOGTT using the regression equation derived from multiple linear regression that was highly correlated with ISIClamp (r = 0.79). In contrast, our study demonstrated a poor correlation between the ISIOGTT developed by Stumvoll et al. and the ISIClamp (r = 0.508). The plausible explanation for the discrepancy is that the equation derived by Stumvoll et al. (4) included BMI and was obtained from obese European (BMI, 19.745.8 kg/m2), whereas all subjects in our study were Asian, and most of them were lean. It is well known that the relationship between the percent body fat and BMI is different among different ethnic groups. For a given value of BMI, Asians have higher body fat than Caucasians (after correction for age and gender) (20, 21). Furthermore, body fat, especially visceral fat, is a major determinant of insulin resistance (22). Therefore, Asians should have higher degrees of insulin resistance than Caucasians at the same BMI. When the equation of ISIOGTT developed by Stumvoll et al. (4) was applied to Asians, such as in our study population, a substantially lower correlation was found.
We concluded that our equation was valid and superior to other equations of ISI derived from fasting and OGTT measurements of glucose and insulin in assessing the insulin sensitivity in subjects with normal glucose tolerance. Further studies in subjects with impaired glucose tolerance and diabetes mellitus should be performed to confirm the validity of this equation.
| Footnotes |
|---|
Abbreviations: AACglu, Area above the glucose curve; AUCglu, area under the glucose curve; AUCins, area under the insulin curve; BMI, body mass index; BW, body weight; FPG, fasting plasma glucose concentration; ISI, insulin sensitivity index; ISIClamp, insulin sensitivity index obtained from glucose clamp; ISIOGTT, insulin sensitivity index obtained from oral glucose tolerance test; OGTT, oral glucose tolerance test; PPGC-without insulin, postloading plasma glucose concentration without insulin; Uglu, glucose appearing in the urine.
Received July 18, 2002.
Accepted November 20, 2002.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y. Zhang, X. Li, D. Zou, W. Liu, J. Yang, N. Zhu, L. Huo, M. Wang, J. Hong, P. Wu, et al. Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2559 - 2565. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Due, T. M Larsen, K. Hermansen, S. Stender, J. J Holst, S. Toubro, T. Martinussen, and A. Astrup Comparison of the effects on insulin resistance and glucose tolerance of 6-mo high-monounsaturated-fat, low-fat, and control diets Am. J. Clinical Nutrition, April 1, 2008; 87(4): 855 - 862. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Anderwald, M. Anderwald-Stadler, M. Promintzer, G. Prager, M. Mandl, P. Nowotny, M. G. Bischof, M. Wolzt, B. Ludvik, T. Kastenbauer, et al. The Clamp-Like Index: A novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects Diabetes Care, September 1, 2007; 30(9): 2374 - 2380. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Rutter, J. B. Meigs, L. M. Sullivan, R. B. D'Agostino Sr, and P. W. Wilson Insulin Resistance, the Metabolic Syndrome, and Incident Cardiovascular Events in the Framingham Offspring Study Diabetes, November 1, 2005; 54(11): 3252 - 3257. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Arnlov, M. J. Pencina, B.-H. Nam, J. B. Meigs, C. S. Fox, D. Levy, R. B. D'Agostino, and R. S. Vasan Relations of Insulin Sensitivity to Longitudinal Blood Pressure Tracking: Variations With Baseline Age, Body Mass Index, and Blood Pressure Circulation, September 20, 2005; 112(12): 1719 - 1727. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chen, G. Sullivan, and M. J. Quon Assessing the Predictive Accuracy of QUICKI as a Surrogate Index for Insulin Sensitivity Using a Calibration Model Diabetes, July 1, 2005; 54(7): 1914 - 1925. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Legro, P. Chiu, A. R. Kunselman, C. M. Bentley, W. C. Dodson, and A. Dunaif Polycystic Ovaries Are Common in Women with Hyperandrogenic Chronic Anovulation but Do Not Predict Metabolic or Reproductive Phenotype J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2571 - 2579. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Manning, W. H.F. Sutherland, R. J. Walker, S. M. Williams, S. A. de Jong, A. R. Ryalls, and E. A. Berry Effect of High-Dose Vitamin E on Insulin Resistance and Associated Parameters in Overweight Subjects Diabetes Care, September 1, 2004; 27(9): 2166 - 2171. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tripathy, P. Almgren, T. Tuomi, and L. Groop Contribution of Insulin-Stimulated Glucose Uptake and Basal Hepatic Insulin Sensitivity to Surrogate Measures of Insulin Sensitivity Diabetes Care, September 1, 2004; 27(9): 2204 - 2210. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ten and N. Maclaren Insulin Resistance Syndrome in Children J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2526 - 2539. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Yeckel, R. Weiss, J. Dziura, S. E. Taksali, S. Dufour, T. S. Burgert, W. V. Tamborlane, and S. Caprio Validation of Insulin Sensitivity Indices from Oral Glucose Tolerance Test Parameters in Obese Children and Adolescents J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1096 - 1101. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |